Quality of Life and Guidelines for PSA Screening
Author:
- Harold C. SoxHSHarold C. Sox
- 16 August 2012
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (7) , 669-671
Abstract
In this issue of the Journal, a study by Heijnsdijk et al.1 shows the way to a resolution of the long-standing controversy about screening for prostate cancer. This is welcome news, since the 2009 reports of the long-awaited European and North American randomized trials of prostate-specific antigen (PSA) screening did not settle the matter.2,3 In the American trial, screening did not reduce prostate-cancer mortality, but the results were confounded by frequent PSA screening in the control group (e.g., 52% in the sixth year).3 In the European Randomized Study of Screening for Prostate Cancer, the screening of men between the . . .Keywords
This publication has 8 references indexed in Scilit:
- Quality-of-Life Effects of Prostate-Specific Antigen ScreeningNew England Journal of Medicine, 2012
- Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2012
- Prostate-Cancer Mortality at 11 Years of Follow-upNew England Journal of Medicine, 2012
- Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2011
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer ScreeningBJU International, 2003
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI: Journal of the National Cancer Institute, 2003